Schmidt-Kraepelin Christian, Engelke Christina, Kahl Kai G, Cordes Joachim
Department of Psychiatry, Social Psychiatry and Psychotherapy, Centre for Mental Health, Medical University Hannover (MHH), Hannover, Germany.
J Clin Psychopharmacol. 2018 Dec;38(6):612-617. doi: 10.1097/JCP.0000000000000957.
Treatment of schizophrenia with depot medication has advantages compared with oral medication, and among these include an improved compliance. Despite such advantages, prescription rates in many European countries are lower than 20%. The aim of this survey was to study the attitudes toward depot medication among the German general population. To the best of our knowledge, only selective samples have been investigated up until now.
A representative sample of 754 people were interviewed via telephone by a professional market research and polling organization. The questionnaire queried demographic characteristics, experience with medication, and the treatment of mental disorders. Subjects' attitudes toward medication in general, long-term medication, and depot medication were surveyed.
Most (66.7%) of the subjects stated that they would be willing to receive depot medication. Subjects who experienced the treatment of mental disorders were more likely to be willing to receive depot medication. Among the reasons for not using depot medication, "fear of injection" (66.3%) and "more self-control when taking medication as tablets" (48.9%) were stated as the most frequent reasons.
This study found a good acceptance of antipsychotic depot medication among the German general population in terms of willingness to receive such treatment. We argue that the clinical practitioners' assumptions that depot formulations would be refused by many patients are unsubstantiated.
与口服药物相比,使用长效药物治疗精神分裂症具有优势,其中包括提高依从性。尽管有这些优势,但许多欧洲国家的长效药物处方率低于20%。这项调查的目的是研究德国普通人群对长效药物的态度。据我们所知,到目前为止仅对选择性样本进行了调查。
一个专业的市场研究和民意调查组织通过电话采访了754人的代表性样本。问卷询问了人口统计学特征、用药经历以及精神障碍的治疗情况。调查了受试者对一般药物、长期药物和长效药物的态度。
大多数(66.7%)受试者表示愿意接受长效药物治疗。有精神障碍治疗经历的受试者更有可能愿意接受长效药物治疗。在不使用长效药物的原因中,“害怕打针”(66.3%)和“服用片剂药物时更能自我控制”(48.9%)被列为最常见的原因。
就接受此类治疗的意愿而言,本研究发现德国普通人群对长效抗精神病药物接受度良好。我们认为临床医生关于许多患者会拒绝长效制剂的假设没有依据。